A Norwegian court has ruled that a generic formula of Lipitor made by drugmaker Ranbaxy does not infringe on Pfizer's patents on the cholesterol-lowering med. This decision could clear the way for a generic version of the medication. Pfizer, which makes Lipitor, has vowed to appeal the ruling.
Read moreDrugmaker Pfizer has once again stopped a generic form of Lipitor from hitting the market. A Danish court has issued an injunction to stop Ranbaxy... Read more »
An ongoing legal battle between Lipitor maker Pfizer and generic drugmaker Ranbaxy may have reached a turning point. A U.S. court has ruled that one... Read more »
Don't expect a cheaper alternative to Lipitor--or similar cholesterol-lowering drugs--anytime soon. A U.S. court ruling blocks generic competitors... Read more »
A British appellate court has upheld a previous ruling barring Ranbaxy Laboratories Ltd. from making a generic form of Lipitor before the expiration... Read more »
A patent dispute agreement between drugmaker Pfizer and generic drugmaker Ranbaxy Laboratories Ltd. means that generic versions of the cholesterol... Read more »